LeaderPortfolio
Baumbach
F
Rank #610
GERMANYHealthcarePharma

Franz von Baumbach

Net Worth
$6.589B
0% (24h)
Franz von Baumbach, a 24-year-old German citizen, is an heir to the Boehringer Ingelheim fortune, a leading pharmaceutical company. His wealth stems from his stake in the family business, positioning him as a prominent figure in the healthcare industry. With a net worth of $6.6 billion, von Baumbach exemplifies the influence of inherited wealth in the modern pharmaceutical landscape. His career, though private, is connected to one of the largest privately-held pharmaceutical companies in the world. The company has a global presence in 130 markets and is known for its innovative medicines.

The Full Dossier

Early Life

Franz von Baumbach, born in Germany, is part of the fourth generation of the Boehringer and von Baumbach families, who continue to manage the company's fortunes.

Rise to Success

Franz von Baumbach's wealth comes from his inheritance from Boehringer Ingelheim, a pharmaceutical company founded in 1885 by Albert Boehringer. The company grew by making ingredients for pharmacies, textile merchants, and the food industry. Today, Boehringer Ingelheim's most well-known drugs treat COPD, anti-coagulation, and type 2 diabetes, with a presence in 130 markets.

Key Business Strategies

Boehringer Ingelheim, being a privately-owned company, focuses on long-term, sustainable actions. The company's strategy includes sound financing and organic corporate growth. In 2015, Hubertus von Baumbach, a member of the family, became the CEO.

Philanthropy

The exact amount of Franz von Baumbach's direct philanthropic contributions is not readily available through the search results. However, as a member of the Boehringer Ingelheim family, he is connected to a company that provides the anti-HIV drug Viramune free of charge to developing countries to help prevent mother-to-child transmission.

Career Timeline

2001

Joined Boehringer Ingelheim

Joined the family's pharmaceutical company, Boehringer Ingelheim.

Philanthropic Impact

HealthcareInformation not available

Viramune

Boehringer Ingelheim provides the anti-HIV drug Viramune free of charge to developing countries to help prevent mother-to-child transmission.

Wealth Trajectory